• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
TWST

TWST

Twist Bioscience Corporation

NASDAQHealthcareMedical - Diagnostics & ResearchUS

USD72.33

+2.18 (+3.11%)

Rating:C-

Company Profile

CEO

Emily Marine Leproust

IPO Date

2018-10-31

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Exchange

NASDAQ

Country

US

Market Metrics

Open

$69.97

Prev. Close

$70.15

Day Low

$68.83

Day High

$72.92

52W Low

$23.30

52W High

$72.99

Market Cap

$4.50B

Volume

1.43M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

38.5%

Avg Negative

3.2%

Avg Neutral

58.3%

News Feed

Twist Bioscience Scoops Up NGS Library Prep Tools Developer For $35M

Benzinga·6/30/2021·↑ positive

Twist Bioscience: Finding An Acceptable Valuation

Seeking Alpha·6/28/2021·↓ negative

Dovetail Genomics Announces New Capture Hi-C Targeted Enrichment Panels

PRNewsWire·6/16/2021·↑ positive

4 Unstoppable Healthcare Stocks to Buy on the Dip

The Motley Fool·5/26/2021·↑ positive

Twist Bioscience Launches Enzymatic Fragmentation Library Preparation Kit for High Uniformity, High-Yield Amplification, Streamlined Next Generation Sequencing Workflow for Targeted Applications

Business Wire·5/25/2021·↑ positive

What Are the Risks With Twist Bioscience?

The Motley Fool·5/8/2021·↑ positive

Twist Bioscience Corporation (TWST) CEO Dr. Emily Leproust on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·5/7/2021·↓ negative

Twist Bioscience (TWST) Expected to Beat Earnings Estimates: Should You Buy?

Zacks Investment Research·4/29/2021·↑ positive

Is a Beat in the Cards for Twist (TWS) This Earnings Season?

Zacks Investment Research·4/29/2021·↑ positive

AcornMed Selects Twist Bioscience Technology to Power Next Generation Precision Medicine Tests

Business Wire·4/7/2021·↑ positive